Please assess the completion status of the following clinical trial:

Trial Title: PTH & Ibandronate Combination Study (PICS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female~* Aged 55-75 years, inclusive, at randomization~* Postmenopausal for \>= 5 years (no menses for at least 5 years)~* Have an evaluable bone mineral density scan (DXA) at the spine AND at the hip with a T-score \<= -1.5 either at the spine or the femoral neck or total hip OR have a T-score \<= -1.0 with at least one of the following risk factors for fracture: 1)Age \>= 65 years; 2)History of post-menopausal fracture (non-vertebral or vertebral); 3)Maternal history of hip fracture.~* Be willing and able to self-administer daily injections~* Signed written consent form.~Exclusion Criteria:~* History of more than 12 months of oral bisphosphonate use ever, or any use (\>4 weeks) with the past 12 months. For those with 4 weeks to 12 months of previous use, a 24 month washout is required.~* History of any IV bisphosphonate use.~* History of more than 12 month of PTH use ever, or any use (\>4 weeks) with the past 12 months.~* History of estrogen (oral or patch) more than one month in the last 6 months or for more than 12 months in the last 2 years.~* Have type 1 or uncontrolled type 2 diabetes mellitus (defined as hemoglobin A1C \> 10.0), or currently using insulin.~* Have serum calcium \>10.2 mg/dl.~* Have Vitamin D level \<15 nanograms/ml.~* Have Stage III renal insufficiency where calculated creatinine clearance \< 40 ml/min by MDRD.~* Have any history of kidney stones in the last 10 years.~* Have any history of hypercalcuria or currently have urine calcium \>300 mg/24 hours.~* Have any history of hypercalcemia.~* Have any history of sarcoidosis.~* Have any history of hyperparathyroidism.~* Have any history of active or treated tuberculosis or other granulomatous disorders.~* History of breast cancer, melanoma or hematologic malignancy which has required treatment within the last 10 years.~* Any history of bone cancer or Paget's disease of bone~* Any other metabolic bone disease which has required treatment within the last 10 years.~* History of any other non-skin cancer which has required treatment within the last 10 years.~* Have a documented history of symptomatic esophageal reflux, achalasia or esophageal stricture.~* Be currently taking \> 7.5 mg systemic prednisone or equivalent per day or for more than 10 days in the last 3 months.~* Be currently using \> 2 puffs, 4 times / day of inhaled steroids.~* Be currently taking anticoagulants.~* Be currently taking anticonvulsants that alter hepatic vitamin D clearance~* Have used Calcitonin within the past 3 months.~* Have used Raloxifene in the last 6 months or for more than 12 months in the last 2 years.~* Have used Tamoxifen in the last 6 months or for more than 12 months in the last 2 years.~* Have used fluoride for at least a month within the past 5 years.~* Be currently taking \> 1000 IU/day Vitamin D~* Using Vitamin D analogues or metabolites.~* Be currently taking thyroid hormone replacement AND have a TSH \< 0.1mIU/L.~* Have any major life-threatening illness.~* Concurrent enrollment in another double-blinded clinical treatment intervention study.~* Life expectancy less than 3 years~* Willing to discontinue all over the counter nutritional supplements

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- A: 6 months both + 18 months oral only (Type: ACTIVE_COMPARATOR): Group A will receive 6 months of monthly oral ibandronate 150 mg, plus daily PTH 1-84, 1.4 mg; followed by 18 months of ibandronate only. Placebo injections will be given months 13-15. Calcium + Vitamin D supplements, plus multivitamins are provided.
- B: (3 months injection + 9 months oral) x 2 years (Type: ACTIVE_COMPARATOR): Group B will receive 3 months of daily PTH 1-84, 1.4 mg; followed by 9 months of monthly oral ibandronate, 150 mg in year 1. In year 2, the group will receive another 3 months of daily PTH 1-84; followed by 9 months of monthly ibandronate. Placebo monthly pills will be given months 1-3 and months 13-15, and placebo injections will be given months 4-6. Calcium + Vitamin D supplements, plus multivitamins are provided.

Based on this trial design, predict the completion outcome and termination type (if applicable).